MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 15, 2006; DOI: 10.1124/mol.106.029868


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.029868v1
71/3/902    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tian, G.
Right arrow Articles by Scott, C. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tian, G.
Right arrow Articles by Scott, C. W


Received for publication August 11, 2006.
Revised December 15, 2006.
Accepted for publication December 15, 2006.

Neurokinin-3 Receptor Specific Antagonists Talnetant and Osanetant Show Distinct Mode of Action in Cellular Ca2+ Mobilization but Display Similar Binding Kinetics and Identical Mechanism of Binding in Ligand Cross-Competition

Gaochao Tian 1*, Dee Wilkins 1, Clay W Scott 1

1 AstraZeneca Pharmaceuticals

* Address correspondence to: E-mail: gaochao.tian{at}astrazeneca.com

Abstract

Talnetant and osanetant, two structurally diverse antagonists of neurokinin-3 receptor (NK3), displayed distinct modes of action in Ca2+ mobilization. While talnetant showed a normal Schild plot with a slope close to unity and a Kb similar to its Ki in binding, osanetant presented an aberrant Schild with a steep slope (3.3 ± 0.5) and a Kb (12 nM) significantly elevated as compared to its Ki (0.8 nM) in binding. Kinetic binding experiments indicated a simple one-step binding mechanism with relatively fast on- and off-rates for both antagonists, arguing against slow onset of antagonism as the reason for abnormal Schild. This conclusion was supported by prolonged preincubation of antagonist that failed to improve the observed aberrant Schild. In ligand cross-competition binding, both talnetant and osanetant displayed linear reciprocal plots of identical slope when [MePhe7]NKB was used as the other competition partner with [125I][MePhe7]NKB as the radioligand, indicating competitive binding of either antagonist with regard to [MePhe7]NKB. Similar patterns were obtained when talnetant was tested against osanetant, indicating competitive binding between the two antagonists as well. These results were reproduced when [3H]SB222200, a close derivative of talnetant, was used as the radioligand. Taken together, these data strongly suggest binding of both talnetant and osanetant at the orthosteric binding site with similar kinetic properties, and do not support the hypothesis that the aberrant Schild observed in functional assays for osanetant is derived from differences in the mechanism of binding for these NK3 antagonists.


Key words: Neuropeptides, Tachykinin, Receptor binding studies


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
P. Malherbe, C. Bissantz, A. Marcuz, C. Kratzeisen, M.-T. Zenner, J. G. Wettstein, H. Ratni, C. Riemer, and W. Spooren
Me-Talnetant and Osanetant Interact within Overlapping but Not Identical Binding Pockets in the Human Tachykinin Neurokinin 3 Receptor Transmembrane Domains
Mol. Pharmacol., June 1, 2008; 73(6): 1736 - 1750.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics